Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis

December 1986

NTIS order #PB87-177465

HEALTH TECHNOLOGY CASE STUDY 37

Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis

DECEMBER 1886



Recommended Citation:

U.S. Congress, Office of Technology Assessment, *Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis* (Health Technology Case Study 37), OTA-HCS-37 (Washington, DC: U.S. Government Printing Office, December 1986).

Library of Congress Catalog Card Number 85-600596

For sale by the Superintendent of Documents U.S. Government Printing Office, Washington, DC *20402*

Preface

Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis is Case Study 37 in OTA's Health Technology Case Study Series. This case study has been prepared in response to a request by the Senate Committee on Appropriations.

OTA case studies are designed to fulfill two functions. The primary purpose is to provide OTA with specific information that can be used in forming general conclusions regarding broader policy issues. The first 19 cases in the Health Technology Case Study Series, for example, were conducted in conjunction with OTA's overall project on The Implications of Cost-Effectiveness Analysis of Medical Technology. By examining the 19 cases as a group and looking for common problems or strengths in the techniques of cost-effectiveness or cost-benefit analysis, OTA was able to better analyze the potential contribution that those techniques might make to the management of medical technology and health care costs and quality.

The second function of the case studies is to provide useful information on the specific technologies covered. The design and the funding levels of most of the case studies are such that they should be read primarily in the context of the associated overall OTA projects. Nevertheless, in many instances, the case studies do represent extensive reviews of the literature on the efficacy, safety, and costs of the specific technologies and as such can stand on their own as a useful contribution to the field.

Case studies are prepared in some instances because they have been specifically requested by congressional committees and in others because they have been selected through an extensive review process involving OTA staff and consultations with the congressional staffs, advisory panel to the associated overall project, the Health Program Advisory Committee, and other experts in various fields. Selection criteria were developed to ensure that case studies provide the following:

 examples of types of technologies by function (preventive, diagnostic, therapeutic, and rehabilitative);

- examples of types of technologies by physical nature (drugs, devices, and procedures);
- examples of technologies in different stages of development and diffusion (new, emerging, and established);
- examples from different areas of medicine (e.g., general medical practice, pediatrics, radiology, and surgery);
- examples addressing medical problems that are important because of their high frequency or significant impacts (e. g., cost);
- examples of technologies with associated high costs either because of high volume (for lowcost technologies) or high individual costs;
- examples that could provide information material relating to the broader policy and methodological issues being examined in the particular overall project; and
- examples with sufficient scientific literature.

Case studies are either prepared by OTA staff, commissioned by OTA and performed under contract by experts (generally in academia), or written by OTA staff on the basis of contractors' papers.

OTA subjects each case study to an extensive review process. Initial drafts of cases are reviewed by OTA staff and by members of the advisory panel to the associated project. For commissioned cases, comments are provided to authors, along with OTA's suggestions for revisions. Subsequent drafts are sent by OTA to numerous experts for review and comment. Each case is seen by at least 30 reviewers, and sometimes by 80 or more outside reviewers. These individuals may be from relevant Government agencies, professional societies, consumer and public interest groups, medical practice, and academic medicine. Academicians such as economists, sociologists, decision analysts, biologists, and so forth, as appropriate, also review the cases.

Although cases are not statements of official OTA position, the review process is designed to satisfy OTA's concern with each case study's scientific quality and objectivity. During the various stages of the review and revision process, therefore, OTA encourages, and to the extent possible requires, authors to present balanced information and recognize divergent points of view.

Health Technology Case Study Series

Case Study Case study title; author(s); Series No. OTA Publication number? Formal Analysis, Policy Formulation, and End-Stage Renal Disease; Richard A. Rettig (OTA-BP-H-9(1)) ** Richard A. Rettig (OTA-BP-H-9(1)) ** The Feasibility of Economic Evaluation of Diagnostic Procedures: The Wagner (OTA-BP-H-9(1)) ** Series No. OTA publication number? Assessment of Four Common X-Ray Procedures: Juditin L. Wagner (OTA-BP-H-9(1)) ** Madavery Rassive Restrain Systems in Automobiles: Issues and Evidence. Wagner (OTA-BP-H-9(1)) ** Seriesing for Colon Carner: A Technology Assessment: David M. Eddy (OTA-BP-H-9(1)) ** Cost Effectiveness of Automated Multichannel Chemistry Analyzers: Milton C. Weinstein and Lauric A. Pearlman (OTA-BP-H-9(1)) ** Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique: Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(8)) ** Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique: Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(8)) ** Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique: Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(8)) ** Province Restriction to Cervical Canner Screening: Bryan R. Luce (OfRe of Technology Assessment) (OTA-BP-H-9(8)) ** The Cost Effectiveness of Upper Gastrointestinal Endoscopy: Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8)) ** The Cost Effectiveness of Number Periodonal Disease: Costs in the Washington, D.C. Archoder (OTA-BP-H-9(8)) ** The Cost Effectiveness of Number Periodonal Disease: Costs in the Washington, D.C. Archoder (OTA-BP-H-9(1)) ** The Cost Effectiveness of Number Periodonal Disease: Costs in the Washington, D.C. Archoder (OTA-BP-H-9(1)) ** The Cost Effectiveness of Number Periodonal Disease: Costs in the Washington, D.C. Archoder (OTA-BP-H-9(1)) ** The Cost Effectiveness of Number Periodonal Disease: Costs in the Washington, D.C. Archoder (OTA-BP-H-9(1)) ** The Cost Effectiveness of Number Periodonal Disease: Costs in the Washington, D.C. Archo		Health Technology Case Study Series ^a				
Series No. OTA publication number	Cas	e Study Case study title; author(s);	Cas	se Study Case study title; author(s);		
Disease: Richard A. Rettig (OTA-BP-H-9(I)) The Feasibility of Economic Evaluation of Diagnostic Procedures: The Case of CT Scanning: Judith L. Wagner (OTA-BP-H-9(2)) Screening for Colon Cancer A Technology Assessment; David M. Eddy (OTA-BP-H-9(3)) Cost Effectiveness of Automated Multichannel Chemistry Analyzers: Milton C. Weinstein and Laurie A. Pearlman (OTA-BP-H-9(I)) Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique: Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(I)) The Cost Effectiveness of Bone Marrow Transplant Therapy and lis Policy Implications: Suard OS colweitzer and C. C. Scalzi (OTA-BP-H-9(B)) Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening: Byan R. Luce Office of Technology Assessment) (OTA-BP-H-9(I)) The Cost Effectiveness of Upper Gastrointestinal Endoscopy: Jonal-Lan Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(I)) The Cost Sand Effectiveness of Neonatal Intensive Care: Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Am Heinen (OTA-BP-H-9(I)) The Cost sand Effectiveness of Neonatal Intensive Care: Peter Budetti, Peggy McManus, Nancy Barrand, and Relative Costs in the Washington, D. C. Area; Richard M. Scheffler and Morpan Delaney (OTA-BP-H-9(I)) Cost Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Uter Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(II)) Cost Benefit Costs in the Washington, D. C. Area; Richard M. Scheffler and Morpan Delaney (OTA-BP-H-9(II)) Elective Hysterectomy: Costs, Risks, and Benefits: Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Ross, and John P. Bunker (OTA-BP-H-9(II)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Ross, and John P. Bunker (OTA-BP-H-9(II)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Ross, and John P. Bunker (OTA-BP-H-9(II)) Elective Hysterectomy: Costs, Risks, and Bene			Seri	ries No. OTA publication number ^b		
Richard A. Rettig (OTA-BP-H-9(II))* 20 The Feasibility of Economic Evaluation of Diagnostic Procedures: The Case of CT Scanning. Judith L. Wagner (OTA-BP-H-9(3)) 3 Screening for Colon Cancer: A Technology Assessment; David M. Eddy (OTA-BP-H-9(3)) 4 Cost Effectiveness of Automated Multichannel Chemistry Analyzers: Milton C. Weinstein and Laurie A. Pearlman (OTA-BP-H-9(B)) 5 Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique. Richard M. Scheffler and Sheldon Rovin (The Cost Effectiveness of Bone Marrow Transplant Therapy and its Policy Implications: Suard O. Schweitzer and C. C. Scalz (OTA-BP-H-9(B)) 7 Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening: Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(B)) 8 The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(B)) 9 The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(B)) 10 The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy MedManus, Nancy Barrand, and Relative Costs in the Washington, D. C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(B)) 12 Assessing Selecti Despiratory Therapy Modalities: Trends and Relative Costs in the Washington, D. C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(B)) 14 Cost Benefit Cost Effectiveness of Medical Technologies A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(B)) 15 Cardiac Radionuclide Imaging and Cost Effectiveness of Medical Technologies A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(B)) 16 The Costs and Effectiveness of Medical Technologies A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(B)) 17 Surgery for Breast Cancer; Raren Schachter Weingrod and Duncan Neuhauser (OTA-BP-H-9(B)) 18 The Costs and Effecti	1		19			
2 The Feasibility of Economic Evaluation of Diagnostic Procedures: The Case of CT Scanning: Judith L. Wagner (OTA.BP.H-9(3)) Screening for Colon Cancer: A Technology Assessment; David M. Eddy (OTA-BP.H-9(3)) Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique; Richard M. Scheffler and Sheldon Rovin (OTA.BP.H-9(4)) Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique; Richard M. Scheffler and Sheldon Rovin (OTA.BP.H-9(3)) The Costs Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications: Starat O. Schweizer and C. Scalzi (OTA.BP.H-9(6)) Allocating Costs and Benefits in Disease Prevention Programs: (OTA.BP.H-9(3)) The Costs Effectiveness of Venoratal Intensive Care: Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Am Heimen (OTA-BP.H-9(9)) The Artificial Heart Cost, Risks, and Benefits: Deborah P. Lubeck and John P. Bunker (OTA-BP.H-9(9)) The Costs and Effectiveness of Neonatal Intensive Care: Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Am Heimen (OTA-BP.H-9(1)) Reaft and Cost Analysis of Medical Interventions: The Case of Cimetifice and Peptic Uter Pissease: Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP.H-9(1)) Reaft and Cost Analysis of Medical Interventions: The Case of Cimetifice and Peptic Uter Disease: Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP.H-9(1)) Reaft and Cost Analysis of Medical Interventions: The Case of Cimetifice and Peptic Uter Disease: Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP.H-9(1)) Reaft and Cost Analysis of Medical Interventions: The Case of Cimetifice and Peptic Uter Disease: Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP.H-9(1)) Reaft and Cost Analysis of Medical Interventions: The Case of Cimetifice and Peptic Uter Disease: Harvey V. Fineberg and Cost Effectiveness (OTA-BP.H-9(1)) Reaft and Cost Analysis of Medical Interventions: A case Study of Orthopedic Ionit Implants; Car			20			
Judith L. Wagner (OTA-BP-H-9(2)) Screening for Colon Cancer: A Technology Assessment; David M. Eddy (OTA-BP-H-9(3)) Cost Effectiveness of Automated Multichannel Chemistry Analyzers: Milton C. Weinstein and Laurie A. Pearlman (OTA-BP-H-9(4)) Periodonial Disease: Assessing the Effectiveness and Costs of the Keyes Technique: Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(5)) The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications: Suard to Schweilzer and C. C. Scalzi (OTA-BP-H-9(6)) Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening: Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7)) The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8)) The Artificial Heart: Cost. Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(1)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimedidne and Peptic Ulcer Disease: (OTA-BP-H-9(1)) Seasons Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(1)) Cast Benefit/Cost Effectiveness of Morgan Delaney (OTA-BP-H-9(7)) Cast Benefit/Cost Effectiveness of Morgan Delaney (OTA-BP-H-9(7)) Cast Benefit/Cost Effectiveness of Morgan Delaney (OTA-BP-H-9(7)) Cast Benefit/Cost Effectiveness of Morgan Delaney (OTA-BP-H-9(1)) Cast Benefit/Cost Effectiveness of Morgan Delaney (OTA-BP-H-9(1)) Flee Costs and Effectiveness of Morgan Delaney (OTA-BP-H-9(1)) Cast Benefit/Cost Effectiveness of Morgan Delaney (OTA-BP-H-9(1)) Cast Benefit/Cost Effectiveness of Morgan Delaney (OTA-BP-H-9(1)) Cast Benefit/Cost Effectiveness of Morgan Delaney (OTA-BP-H-9(1)) C	2	The Feasibility of Economic Evaluation of Diagnostic Pro-				
3 Screening for Colon Cancer: A Technology Assessment; David M. Eddy (OTA-BP-H-9(3)) 4 Cost Effectiveness of Automated Multichannel Chemistry Analyzers: Milton C. Weinstein and Laurie A. Pearlman (OTA-BP H-9(4)) 5 Perfordontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique: Richard M. Scheffler and Sheldon Rovin (OTA-BP H-9(1)) 6 The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Polity Implications: Stuart O. Schweilzer and C. C. Scalzi (OTA-BP-H-9(6)) 7 Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening: Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(8)) 8 The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(8)) 10 The Costs and Effectiveness of Noenatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Am Heinen (OTA-BP-H-9(10)) 11 Benefit and Cost Amalysis of Medical Interventions: The Cost of Climetidine and Peptic Ulcer Disease: Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) 12 Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D. C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) 15 Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Mitchael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(14)) 15 Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Mitchael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(18)) 16 The Costs and Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants: Judith D. Bentlow: and Philip G. Drev (OTA-BP-H-9(18)) 16 The Costs and Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants: Judith D. Bentlow: and Philip G. Drev (OTA-BP-H-9(18)) 16 The Costs and Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants: Judith D. Bentlow: and Philip G. Drev (OTA-BP-H-9(18)) 16 The Costs and Effectiveness of Me			91			
David M. Eddy (OTA.BP.H-9(3)) Cost Effectiveness of Automated Multichannel Chemistry Analyzers: Milton C. Weinstein and Laurie A. Pearlman (OTA.BP.H-9(4)) Periodonial Disease: Assessing the Effectiveness and Costs of the Keyes Technique: Richard M. Scheffler and Sheldon Rovin (OTA.BP.H-9(5)) The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications: Suard O. Schweitzer and C. C. Scalzi (OTA.BP.H-9(6)) Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Caneer Screening: Bryan R. Luce (Office of Technology Assessment) (OTA.BP.H-9(8)) The Cost Effectiveness of Upper Gastrointestinal Endoscopy: Jonathan A. Showstack and Steven A. Schroeder (OTA.BP.H-9(8)) The Artificial Heart: Cost. Risks, and Benefits: Deborah P. Lubeck and John P. Bunker (OTA.BP.H-99(1)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease: Harvey V. Firneberg and Laurie A. Pearlman (OTA.BP.H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA.BP.H-9(12)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith B. Rander Morgan Delaney (OTA.BP.H-9(12)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith B. Rander Morgan Delaney (OTA.BP.H-9(12)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith B. Rander Morgan Delaney (OTA.BP.H-9(18)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith B. Rander Morgan Delaney (OTA.BP.H-9(18)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith B. Asson and Brite Fortess (OTA.BP.H-9(18)) Cost Benefit/Cost Effectiveness of Musical Technologies: A Case Study of Orthopedic Joint Implants; Judith B. Asson and Benefit/Cost	Q		41	9 1		
Millton C. Weinstein and Laurie A. Pearlman (OTA-BP-H-9(I)) Periodorial Disease: Assessing the Effectiveness and Costs of the Keyes Technique; Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(I)) The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications: Stuart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6)) Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening; Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(I)) The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(I)) The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(I)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimeltifine and Peptic Uter Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(II)) Cardiac Radiomuchde Imaging and Cost Effectiveness of Comeltifice and Peptic Uter Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(II)) Cost Benefit and Cost Analysis of Medical Interventions: The Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Phillip G. Drew (OTA-BP-H-9(II)) Cost Benefit Cost Effectiveness of Medical Technologie: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Phillip G. Drew (OTA-BP-H-9(II)) Cost Benefit Cost Effectiveness of Medical Technologie: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Phillip G. Drew (OTA-BP-H-9(II)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(II)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O1-A-BP-H-9(II)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O1-A-BP-H-9(II)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(II)) Elec		David M. Eddy (OTA-BP-H-9(3))		Virginia W. Stern and Martha Ross Redden		
Milton C. Weinstein and Laurie A. Pearlman (OTA-BP-H-9(B)-H) (9(b) Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique: Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(5)) The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications: Suard O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6)) Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Scenesing: Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(8)) The Cost Effectiveness of Upper Gastrointestinal Endoscopy: Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8)) The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9)) The Costs and Effectiveness of Neonatal Intensive Care: Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(16)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimeltidine and Peptic Ulerer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(18)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(18)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopectic Joint Implants; Judith D. Benikover and Phillip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Luconard G. Schiffrin and William J. Rich (OTA-HCS-31) The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-32) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Irwin Litt (OTA-HCS-33) The Cost Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O1-A-BP-H-9(18)) The Efficacy and Cost Effectiveness of Psychotherapy; Leona	4		99	(OTA-BP-H-16(21)) ⁸		
(OTA-BP-H-9(4)) 5 Periodroidal Disease: Assessing the Effectiveness and Costs of the Keyes Technique: Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9(5)) 6 The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications: Suart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6)) 7 Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening: Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7)) 8 The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(9)) 9 The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9)) 10 The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Am Heinen (OTA-BP-H-9(10)) 11 Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(12)) 12 Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D. C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) 13 Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(14)) 14 Cost Benefit/ Cost Effectiveness of Nuers Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) 15 The Costs and Effectiveness of Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(16)) 16 The Costs and Effectiveness of Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(16)) 17 The Costs and Effectiveness of Nerse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) 18 The Sefficacy and Cost Effectiveness of Psychotherapy; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) 19 The Cost Send Effectiveness of Nuers Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) 10 The Costs and Effectiveness of Nuers Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) 11 The Costs			22			
5 Periodontal Disease: Assessing the Effectiveness and Costs of the Keyes Technique; Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9fl) Alba-Pt-19(1) Richard M. Scheffler and Sheldon Rovin (OTA-BP-H-9fl) Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening: Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9fl) Bryan R. Luce (Office of Techno						
the Keyes Technique; Richard M. Scheffler and Sheldon Rovin (OTA-BP.H-9(5)) The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications: Stuart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6)) Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening; Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7)) The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(7)) The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(1)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D. C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(13)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Niese Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O1-A-BP-H-9(18)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Sax (Office of Technology Assessment) (OTA-BP-H-9(18)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Asac (Office of Technology Assessment) (OTA-BP-H-9(18))	5		23			
(OTA-HP-H-9(5)) 6 The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications; Stuart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6)) 7 Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening; Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7)) 8 The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(7)) 9 The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(1)) 10 The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(1)) 11 Assessing Selected Repiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(1)) 12 Assessing Selected Repiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(1)) 13 Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortees (OTA-BP-H-9(14)) 15 Elective Hysterectomy; Costs, Risks, and Benefits Cardia Koudy of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) 16 The Costs and Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(14)) 16 The Costs and Effectiveness of Neonator Solkowitz (OTA-BP-H-9(16)) 17 Surgery for Breast Cancer; Karen Schachter Weingrood and Duncan Neuhauser (O1-A-BP-H-9(18)) 18 The Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18))*						
6 The Cost Effectiveness of Bone Marrow Transplant Therapy and Its Policy Implications: Stuart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6)) 7 Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening: Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(8)) 8 The Cost Effectiveness of Upper Gastrointestinal Endoscopy: Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8)) 9 The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(19)) 10 The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10)) 11 Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptit Ulcer Disease: Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) 12 Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) 13 Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(14)) 14 Cost Benefit Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Benikover and Philip G. Drew (OTA-BP-H-9(14)) 15 Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(14)) 16 The Costs and Effectiveness of Nurse Practitioners: Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) 17 Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O'1-A-BP-H-9(18)) 18 The Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (O'TA-HCS-29) The Contact Lens Industry: Structure, Competition, and Public Policy; Anthony A. Romen dornal Melvyn Menezes (OTA-HCS-33) The Contact Lens Industry: Structure, Competition, and Public Policy; Anthony A. Romen dornal Melvyn Menezes (OTA-HCS-34) The Costs and Effectiveness of Nurse Practitioners: L		Richard M. Scheffler and Sheldon Rovin				
and Its Policy Implications: Stuart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6)) 7 Allocating Costs and Benefits in Disease Prevention Programs: An Application to Cervical Cancer Screening: Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7)) The Cost Effectiveness of Upper Gastrointestinal Endoscopy: Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8)) The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(8)) The Costs and Effectiveness of Neonatal Intensive Care: Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Lauric A. Pearlman (OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(13)) Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(16)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Cost Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Cost Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Cost Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Cost Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Cost Effectiveness of Office of Technology Assessment) (OTA-BP-H-9(18)) The Effectivenes of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Cordon H. DeFriese, Thomas R. Oliver, and Irvin Litt (OTA-HCS-33) The Effect of Federal Policies on Extracorporeal Shock Wave Lithot	6	The Cost Effectiveness of Bone Marrow Transplant Therapy	24			
An Application to Cervical Cancer Screening; Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(T)) 8 The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(B)) 9 The Artificial Heart: Cost, Risks, and Benefits: Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(B)) 10 The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(I0)) 11 Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(I1)) 12 Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(I2)) 13 Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(I4)) 14 Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith Randal (Office of Technology Assessment) (OTA-BP-H-9(I2)) 15 Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(I6)) 16 The Cost Sand Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith Randal (Office of Technology Assessment) (OTA-BP-H-9(I2)) 16 The Cost Sand Effective Messor of Medical Technologies (Appleading Messor of Medical Technologies (Appleading Messor of Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-34) 17 Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O1-A-BP-H-9(I8)) 18 The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(I8))*		and Its Policy Implications;		Health Outcomes;		
An Application to Cervical Cancer Screening: Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7)) The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8)) The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9)) The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits: Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Costs and Effectiveness of Neonatal Intensive Care; Raren Schachter Weingrod and Duncan Neuhauser (O1-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18))*	~	Stuart O. Schweitzer and C. C. Scalzi (OTA-BP-H-9(6))	9.5			
Bryan R. Luce (Office of Technology Assessment) (OTA-BP-H-9(7)) 8 The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8)) 9 The Artificial Heart: Cost, Risks, and Benefits: Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9)) 10 The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10)) 11 Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) 12 Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) 13 Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(18)) 14 Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith Randal (Office of Technology Assessment) 15 Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(16)) 16 The Cost Effectiveness of Necical Technologies: A Case Study of Orthopedic Joint Implants; Judith Randal (Office of Technology Assessment) 16 The Cost Sand Effective Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) 16 The Cost Effective Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) 17 Elective Hysterectomy: Costs, Risks, and Benefits; Lucand Lucand Sancial Learn Industry; Anthony A. Romeo (OTA-HCS-33) 18 The Eost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith Randal (Office of Technology Assessment) 18 The Market Grubs Learn And Alary Cohen (OTA-HCS-30) 19 The Market Grubs Learn And Morgan Delaney (OTA-BP-H-9(12	1		23			
COTA-BP-H-9(7)			26			
The Cost Effectiveness of Upper Gastrointestinal Endoscopy; Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8)) The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9)) The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Cost Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18))			20			
Jonathan A. Showstack and Steven A. Schroeder (OTA-BP-H-9(8)) The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9)) The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(14)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Ludith D. Bentkover and Philip G. Drew (OTA-BP-H-9(16)) Elective Hysterectomy: Costs, Risks, and Benefits; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Costs and Effectiveness of Nurse Practitioners; Karen Schachter Weingrod and Duncan Neuhauser (O1-A-BP-H-9(17)) The Deficiency Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-32) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Mathew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Leonard Save (Office of Technology Assessment) (OTA-BP-H-9(18)) The Effectiveness of Orthopedic Joint Implants; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Costs and Effectiveness of Nurse Practitioners; Karen Schachter Weingrod and Duncan Neuhauser (O1-A-BP-H-9(17)) The Market for Wheelchairs: Innovations and Federal Policy; Donald S. Shepard and Sarita L. Karen (OTA-BP-H-9(16)) The Cost Effectiveness of Digital Subtraction Angiography in the Diagno	8					
The Artificial Heart: Cost, Risks, and Benefits; Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9)) The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(IO)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(II)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Costs and Effectiveness of Muse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Effectacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Effectacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18))			27	Nuclear Magnetic Resonance Imaging Technology: A Clinical,		
Deborah P. Lubeck and John P. Bunker (OTA-BP-H-9(9)) The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(15)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(16)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Costs and Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18))	0					
Decisionmaking: Peter Budetti, Peggy McManus. Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(1O)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Case Study of Orthopedic Joint Implants; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(16)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Cost Sefficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) disconting the Policy; Sandra J. Tanenbaum (OTA-HCS-29) The Boston Elbow; Sandra J. Tanenbaum (OTA-HCS-29) The Market for Wheelchairs: Innovations and Federal Policy; Donald S. Shepard and Sarita L. Karen (OTA-HCS-30) The Contact Lens Industry: Structure, Competition, and Public Policy; Leonard G. Schifrin and William J. Rich (OTA-HCS-31) The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32) The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Joseph Ouslander, Robert Kane, Shira Vollmer, and Irvin Litt (OTA-HCS-34) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Joseph Ouslander, Robert Kane, Shira Vollmer, and Irvin Litt (OTA-HCS-34) The Cost Effectiveness and Costs of Continuous Ambulatory Peritonal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) The Effectiveness	9		98	Earl P. Steinberg and Alan Cohen (OTA-HCS-27)		
The Costs and Effectiveness of Neonatal Intensive Care; Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Benktover and Philip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (O1-A-BP-H-9(17)) The Market for Wheelchairs: Innovations and Federal Policy; Donald S. Shepard and Sarita L. Karen (OTA-HCS-30) The Contact Lens Industry: Structure, Competition, and Public Policy; Leonard G. Schiffrin and William J. Rich (OTA-HCS-31) The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithortipsy Leonard G. Schiffrin and William J. Rich (OTA-HCS-36) The Cost			40			
Peter Budetti, Peggy McManus, Nancy Barrand, and Lu Ann Heinen (OTA-BP-H-9(10)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Boston Elbow; Sandra J. Tanenbaum (OTA-HCS-29) The Market for Wheelchairs: Innovations and Federal Policy; Donald S. Shepard and Sarita L. Karen (OTA-HCS-31) The Contact Lens Industry: Structure, Competition, and Public Policy; Leonard G. Schiffrin and William J. Rich (OTA-HCS-31) The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irvin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Littletoripsy Elain	10					
Lu Ann Heinen (ÖTA-BP-H-9(IO)) Benefit and Cost Analysis of Medical Interventions: The Case of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(II)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(16)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) Cost Benefit (Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irvin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Polices on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-37)			29			
of Cimetidine and Peptic Ulcer Disease; Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) 12 Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) 13 Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) 14 Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) 15 Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(16)) 16 The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) 17 Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O1-A-BP-H-9(17)) 18 The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-HCS-37) 18 The Contact Lens Industry: Structure, Competition, and Public Policy; Leonard G. Schifrin and William J. Rich (OTA-HCS-31) 18 The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32) 18 The Cost Benefit/Cost Effectiveness of Medical Technologies: A Carel Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) 15 Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(16)) 16 The Costs and Effectiveness of Neglectal Technologies: A Carel Study of Orthopedic Joint Implants; Leonard G. Schifrin and William J. Rich (OTA-HCS-31) 18 The Cost Enefit/Cost Effectiveness of Medical Technologies: A Carel Study of Orthopedic Joint Implants; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) 16 The Cost Enefit/Cost Effectiveness of Psychotherapy; Karen Schachter Weingrod and Duncan						
Harvey V. Fineberg and Laurie A. Pearlman (OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) Assessing Selected Respiratory Therapy Modalities: Trends and Public Policy; Leonard G. Schifrin and William J. Rich (OTA-HCS-31) The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (OTA-HCS-37)	11		30			
(OTA-BP-H-9(11)) Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) Streeffectiveness and Costs of Continuous Ambulatory William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithortipsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (OI-A-I-EC-37)			91			
12 Assessing Selected Respiratory Therapy Modalities: Trends and Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) 13 Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) 14 Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) 15 Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) 16 The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) 17 Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) 18 The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ^a Leonard G. Schifrin and William J. Rich (OTA-HCS-31) The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-33) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)		v e	31			
Relative Costs in the Washington, D.C. Area; Richard M. Scheffler and Morgan Delaney (OTA-BP-H-9(12)) 13 Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) 14 Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) 15 Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) 16 The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) 17 Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) 18 The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ^a 32 The Hemodialysis Equipment and Disposable Industry; Anthony A. Romeo (OTA-HCS-32) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)	12					
(OTA-BP-H-9(12)) Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) Technologies for Managing Urinary Incontinence; Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)			32			
Cardiac Radionuclide Imaging and Cost Effectiveness; William B. Stason and Eric Fortess (OTA-BP-H-9(13)) Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ^a Joseph Ouslander, Robert Kane, Shira Vollmer, and Melvyn Menezes (OTA-HCS-33) The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (OTA-I-I-EC-37)				Anthony A. Romeo (OTA-HCS-32)		
William B. Stason and Eric Fortess (OTA-BP-H-9(13)) 14 Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) 15 Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) 16 The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) 17 Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) 18 The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) 18 The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) 19 The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) 10 The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) 10 The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) 11 Surgery for Breast Cancer; Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) 12 Surgery for Breast Cancer; Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) 13 Surgery for Breast Cancer; Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18))	10		33			
 Cost Benefit/Cost Effectiveness of Medical Technologies: A Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Cost and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18))⁴ The Cost Effectiveness of Digital Subtraction Angiography in the Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37) 	13					
Case Study of Orthopedic Joint Implants; Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) Caso Study of Orthopedic Joint Implants; Ithe Diagnosis of Cerebrovascular Disease; Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)	14		34			
Judith D. Bentkover and Philip G. Drew (OTA-BP-H-9(14)) Elective Hysterectomy: Costs, Risks, and Benefits; Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ⁴ Matthew Menken, Gordon H. DeFriese, Thomas R. Oliver, and Irwin Litt (OTA-HCS-34) The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)	• • •		01			
Carol Korenbrot, Ann B. Flood, Michael Higgins, Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ^d The Effectiveness and Costs of Continuous Ambulatory Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)						
Noralou Roos, and John P. Bunker (OTA-BP-H-9(15)) The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ⁴ Peritoneal Dialysis (CAPD) William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)	15					
The Costs and Effectiveness of Nurse Practitioners; Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ⁴ William B. Stason and Benjamin A. Barnes (OTA-HCS-35) Effects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)			35			
Lauren LeRoy and Sharon Solkowitz (OTA-BP-H-9(16)) Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ⁴ Seffects of Federal Policies on Extracorporeal Shock Wave Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)	16					
17 Surgery for Breast Cancer; Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) 18 The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ⁴ Lithotripsy Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)	10	· · · · · · · · · · · · · · · · · · ·	36			
Karen Schachter Weingrod and Duncan Neuhauser (O-I-A-BP-H-9(17)) The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ⁴ Elaine J. Power (Office of Technology Assessment) (OTA-HCS-36) Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)	17					
The Efficacy and Cost Effectiveness of Psychotherapy; Leonard Saxe (Office of Technology Assessment) (OTA-BP-H-9(18)) ^a Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis; (O-I-A-I-EC-37)		Karen Schachter Weingrod and Duncan Neuhauser		Elaine J. Power (Office of Technology Assessment)		
Leonard Saxe (Office of Technology Assessment) Midwives: A Policy Analysis; (OTA-BP-H-9(18)) ^a (O-I-A-I-EC-37)	10		0.77			
(OTA-BP-H-9(18)) ⁴ (O-I-A-I-EC-37)	18		37			
	<u> </u>					

^aAvailable forsale by the Superintendent of Documents, U.S. Government Printing Office, Washington, DC, 20402, and by the National Technical Information Service, 5285 Port Royal Rd., Springfield, VA, 22161. Call OTA's Publishing Office (224-8996) for availability and ordering information.

mation.

bOriginal publication numbers appear in parentheses.

cThe first 17 cases in the series were 17 separately issued cases in Background Paper #2: Case Studies of Medical Technologies, prepared in conjunction with OTA's August 1980 report The Implications of Cost-Effectiveness Analysis of Medical Technology.

dBackground paper #3 to The Implications of Cost-Effectiveness Analysis of

Medical Technology.

eBackground paper #s to The Implications of Cost-Effectiveness Analysis of

Medical Technology.

*Background paper #1 to OTA's May 1982 report Technology and Handicapped People.

8Background paper #2 to Technology and Handicapped People.

OTA Project Staff for Case Study #37 Nurse Practitioners, Physician Assistants, and Certified Nurse-Midwives: A Policy Analysis

Roger C. Herdman, Assistant Director, OTA Health and Life Sciences Division

Clyde J. Behney, Health Program Manager

Gloria Ruby, Project Director

Steven Sisskind, Research Assistant"

Virginia Cwalina, Administrative Assistant

Diann G. Hohenthaner, F'. C. Specialist

Carol A. Guntow, Secretary/Word Processor Specialist

Principal Contractor

Edward G. Brooks, University of North Carolina, Chapel Hill, NC

Contractors

Louis P. Garrison, The Project Hope Health Sciences Education Center, Millwood, VA
Anne Meadows, Washington, DC (Editing)

^{*}From July to October 1986.

Advisory Panel—Nurse Practitioners, Physician Assistants, and Certified Nurse= Midwives: A Policy Analysis

Rosemary Stevens, *Chair*Department of History and the Sociology of Science
University of Pennsylvania, Philadelphia, PA

Walter H. Caulfield Kaiser Permanence Oakland, CA

Philip D. Cleveland Family Medicine Spokane

Spokane, WA Lynn Etheredge

Health Policy Consultant

Washington, DC

Willis Goldbeck

Washington Business Group on Health

Washington, DC

Sandra Greene

Health Economics Research

Blue Cross/Blue Shield of North Carolina

Durham, NC

Hurdis Griffith

Robert Wood Johnson Fellow

Institute of Medicine

National Academy of Sciences

Washington, DC

Charles G. Huntington Hermon Medical Group

Hermon, NY Lauren LeRoy

Physician Payment Review Commission

Washington, 'DC

Kathy Lohr The Rand Corp. Washington, DC

Ruth Lubic

Maternity Center Association

New York, NY

Michael R. Pollard Office of Policy Analysis

Pharmaceutical Manufacturers' Association

Washington, DC

Patricia A. Prescott School of Nursing University of Maryland

Baltimore, MD

Judith Rooks Consultant Portland, OR

George M. Ryan

Department of Obstetrics and Gynecology

College of Medicine University of Tennessee

Memphis, TN

Richard M. Scheffler

Health Policy and Administration Program

School of Public Health University of California

Berkeley, CA

Henry M. Seidel School of Medicine

The Johns Hopkins University

Baltimore, MD

Gerry Shea

Health Care Division

Service Employees International Union

Washington, DC

Barbara Warden

National Consumers' League

Washington, DC

Ivan Williams Kellogg Center

Montreal General Hospital

Montreal, Quebec

NOTE: OTA appreciates and is grateful for the valuable assistance and thoughtful critiques provided by the advisory panel members. The panel does not, however, necessarily approve, disapprove, or endorse this report. OTA assumes full responsibility for the report and the accuracy of its contents,